Corrigendum to 'Efficacy of emicizumab is maintained throughout dosing intervals for bleed prophylaxis' [Research and Practice in Thrombosis and Haemostasis, Volume 7, Issue 2, February 2023, 100077].
Res Pract Thromb Haemost
; 7(4): 100191, 2023 May.
Article
in En
| MEDLINE
| ID: mdl-37538504
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Res Pract Thromb Haemost
Year:
2023
Document type:
Article
Affiliation country:
United States
Country of publication:
United States